The hearing for Alex Azar as the Secretary of Health and Human Services revolved in large part around the drug pricing controversy, and the former drug company executive told a Senate panel that pharmacy benefits managers negotiate drug prices for Medicare Part D, which he said is "the kind of thing where we could save money and improve things for patients" in connection with Part B prescription drugs.